AVIR Completes Enrollment
Atea Pharmaceuticals completes patient enrollment in Phase 3 C-FORWARD trial for Hepatitis C treatment
AVIR - Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus